[FLXN] Flexion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.71 Change: 2.14 (11.52%)
Ext. hours: Change: 0 (0%)

chart FLXN

Refresh chart

Strongest Trends Summary For FLXN

FLXN is in the medium-term down -52% in 1 year. In the long-term down -50% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.24% ROE-21.88% ROI
Current Ratio32.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.69 M Cash From Investing Activities-62.47 M Cash From Operating Activities-9.98 M Gross Profit
Net Profit-9.17 M Operating Profit-9.01 M Total Assets141.02 M Total Current Assets134.24 M
Total Current Liabilities4.16 M Total Debt Total Liabilities4.19 M Total Revenue
Technical Data
High 52 week28.14 Low 52 week11.32 Last close13.4 Last change-4.56%
RSI60.53 Average true range0.88 Beta1.37 Volume629.96 K
Simple moving average 20 days5.93% Simple moving average 50 days-6.49% Simple moving average 200 days-36.48%
Performance Data
Performance Week2.76% Performance Month0.37% Performance Quart-27.37% Performance Half-51.18%
Performance Year-46.46% Performance Year-to-date18.37% Volatility daily4.16% Volatility weekly9.3%
Volatility monthly19.06% Volatility yearly66.03% Relative Volume286.22% Average Volume780.96 K
New High New Low

News

2019-03-11 08:00:07 | Mutual Fund Managers Are Bullish On Stock Market Forecast — But Some Are Hedging Bets

2019-03-04 16:30:00 | Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference

2019-03-04 07:00:00 | Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors

2019-03-01 18:47:32 | Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-03-01 16:45:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-28 20:20:23 | Flexion Therapeutics Inc FLXN Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:01:00 | Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results

2019-02-26 16:30:00 | Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference

2019-02-21 16:30:00 | Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage

2019-02-21 10:31:03 | Flexion Therapeutics FLXN May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-02-20 16:30:00 | Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019

2019-02-11 16:05:00 | Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in Rheumatology and Therapy

2019-02-11 11:41:00 | Here's Why Flexion Therapeutics Rose 29.8% in January

2019-02-08 09:00:00 | Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12

2019-02-01 17:00:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-01-30 07:20:00 | Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality — Fundamental Analysis, Key Performance Indications

2019-01-22 16:30:00 | Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer

2019-01-04 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-01-04 07:59:58 | The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

2019-01-03 16:36:00 | Flexion shares plummet after weak revenue guidance

2019-01-03 16:01:00 | Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019

2019-01-03 12:05:21 | Raymond James: Flexion Therapeutics Estimates Are A Stretch

2019-01-03 10:26:03 | Flexion Starts Phase III Enrollment on Zilretta for Hip OA

2019-01-02 16:30:00 | Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in OA of the Hip and Reports Results from SHIP Study

2018-12-20 16:00:00 | Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019

2018-12-17 16:30:00 | Flexion Therapeutics Submits Supplemental New Drug Application sNDA for ZILRETTA® triamcinolone acetonide extended-release injectable suspension

2018-12-11 11:01:00 | Here's Why Flexion Therapeutics Jumped 20.5% in November

2018-12-04 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-11-28 10:07:00 | 2 Small Biotech Stocks That Insiders Are Buying

2018-11-27 13:53:20 | Flexion Therapeutics Inc NASDAQ:FLXN: What Does Its Beta Value Mean For Your Portfolio?

2018-11-27 08:45:00 | New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-16 09:22:24 | Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe 

2018-11-08 21:37:00 | Edited Transcript of FLXN earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 19:30:12 | Flexion Therapeutics FLXN Reports Q3 Loss, Tops Revenue Estimates

2018-11-07 18:34:28 | Flexion Therapeutics: 3Q Earnings Snapshot

2018-11-07 16:01:00 | Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights

2018-11-05 06:30:00 | Flexion Therapeutics Announces Product-Specific J Code J3304 for ZILRETTA® triamcinolone acetonide extended-release injectable suspension Effective January 1, 2019

2018-10-31 07:30:00 | Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018

2018-10-22 07:30:00 | Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® triamcinolone acetonide extended-release injectable suspension in Bilateral Knee OA at 2018 ACR Annual Meeting

2018-10-16 08:45:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy — New Research Emphasizes Economic Growth

2018-10-05 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-09-10 09:00:00 | Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology

2018-09-07 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2018-08-28 16:30:00 | Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference

2018-08-20 17:23:33 | Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium

2018-08-17 08:00:00 | Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel — Future Expectations, Projections Moving into 2018

2018-08-10 06:19:58 | Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass.

2018-08-07 18:35:10 | Flexion Therapeutics FLXN Reports Q2 Loss, Lags Revenue Estimates

2018-08-07 17:30:52 | Flexion Therapeutics: 2Q Earnings Snapshot

2018-08-07 16:01:00 | Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights